ArticleActa oncologica (Stockholm, Sweden)2025
Collimated and non-collimated proton minibeam irradiation using SIRMIO: a simulation study.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeSuccessful clinical integration of pMBRT requires comprehensive investigations of the relationship between various pMBRT parameters and their associated biological effects. Such investigations are critically dependent on small animal models. Therefore, a state-of-the-art small animal irradiation platform like SIRMIO (Small Animal Proton Irradiator for Research in Molecular Image-guided Radiation-Oncology), capable of delivering precisely controlled spatially fractionated doses, is highly desirable for advancing preclinical pMBRT research. MATERIAL AND
methodsThis in silico study evaluates the SIRMIO beamline's capability to deliver beams essential for pMBRT experiments. We used Geant4-based Monte Carlo simulations to investigate two configurations: one without a collimator, and one using a 30 mm thick brass multislit collimator (MSC). For both configurations, we examined center-to-center (CTC) of 3, 4, and 5 mm, with a constant 1 mm slit width when MSC is used.
resultsThe SIRMIO beamline can effectively generate spatially fractionated dose profiles with varying CTC. Without a collimator, sufficient dose contrast for pMBRT can be achieved with CTC of 4 mm and above, as evidenced by peak-to-valley dose ratios (PVDR) of 3.44 and 6.57 for 4 and 5 mm CTC, respectively. MSC further enhances dose contrast, achieving PVDR of 11.3, 20.7, and 28.7 for 3, 4, and 5 mm CTC, respectively. Furthermore, we explored interlacing beams as a means of achieving a uniform target dose while preserving dose contrast in normal tissue, demonstrating the potential of this approach using the SIRMIO beamline.
interpretationThe SIRMIO platform can be a viable option for pMBRT experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.